Hypothesis

Selective inhibition of the NLRP3 inflammasome in thymic stromal cells maintains protective IL‑6 classical signaling while preventing pathological trans‑signaling, thereby preserving naïve T cell production in aged individuals.

Rationale

• NLRP3 activation raises intrathymic IL‑1β, driving thymic involution and reducing thymic output 1.
• NLRP3 deficiency in aged mice improves T cell reconstitution after HSCT and increases naïve T cell numbers 1.
• Aged macrophages produce less IL‑6, yet IL‑6 can act both as a suppressor of inflammation and as a driver of STAT3‑mediated chronic inflammation via trans‑signaling 2, 3.
• Tocilizumab (IL‑6R blockade) and siltuximab (IL‑6 ligand neutralization) have distinct effects on Tfh, Treg and STAT3 signaling, indicating that classical versus trans‑signaling pathways diverge in function 4.

Mechanistic Insight

We propose that NLRP3 inflammasome activity in thymic epithelial cells (TECs) induces a local shift from membrane‑bound IL‑6R (classical signaling) to increased shedding of soluble IL‑6R (sIL‑6R). The rise in sIL‑6R enables IL‑6 trans‑signaling, which activates STAT3 in nearby thymocytes, promoting apoptosis and skewing differentiation toward inflammatory phenotypes. Simultaneously, NLRP3‑driven IL‑1β amplifies NF‑κB pathways that further upregulate ADAM17, the protease responsible for IL‑6R shedding. Inhibiting NLRP3 therefore reduces IL‑1β, lowers ADAM17 activity, preserves membrane IL‑6R, and sustains classical IL‑6 signaling that supports TEC survival and IL‑7 production, both critical for naïve T cell development.

Testable Predictions

1. In aged mice, pharmacological NLRP3 inhibition (e.g., MCC950) will decrease thymic sIL‑6R levels and increase membrane IL‑6R expression on TECs, measurable by flow cytometry and immunofluorescence.
2. The same treatment will reduce phospho‑STAT3 (Y705) in thymic dendritic cells and double‑positive thymocytes, while increasing STAT5 phosphorylation downstream of IL‑7R.
3. Aged NLRP3‑inhibited mice will show higher frequencies of recent thymic emigrants (RTEs: CD4+CD62L+CD31+) and improved naïve T cell receptor diversity compared with vehicle controls.
4. Adding recombinant sIL‑6R to NLRP3‑inhibited thymic cultures will rescue STAT3 activation and restore thymocyte apoptosis, confirming the trans‑signaling link.
5. In a human HSCT cohort, patients receiving an NLRP3 inhibitor alongside reduced‑intensity conditioning will exhibit higher sIL‑6R to membrane IL‑6R ratios in thymic aspirates (when available) and faster CD4+ naïve T cell reconstitution at 6 months post‑transplant.

Falsifiability

If NLRP3 inhibition fails to alter the sIL‑6R/membrane IL‑6R balance, does not reduce thymic STAT3 phosphorylation, or does not improve naïve T cell output, the hypothesis would be refuted. Conversely, if classical IL‑6 signaling proves dispensable for thymic function (e.g., IL‑6R blockade improves outcomes), the proposed protective role of classical signaling would be challenged.

Conclusion

By coupling NLRP3 inflammasome inhibition with selective preservation of IL‑6 classical signaling, we can target a node that simultaneously dampens inflammasome‑driven IL‑1β toxicity and sustains the cytokine milieu needed for thymopoiesis, offering a refined strategy to combat immunosenescence.